Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

A one-time nasal spray has been approved by the Food and Drug Administration as a standalone treatment for depression.

In today's Health Alert, the FDA has approved the first stand-alone nasal spray to treat drug-resistant depression.

An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...

The U.S. Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with ma ...

Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.

Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...

The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...

A new nasal drug has been approved to treat depression. The drug Spravato  is a nasal spray made by Johnson and Johnson.

The U.S. Food and Drug Administration has approved a nasal spray to treat depression—the first-ever stand-alone medication ...